| Product Code: ETC8567469 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 New Zealand Pharmacogenetic Testing Market Overview |
3.1 New Zealand Country Macro Economic Indicators |
3.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, 2021 & 2031F |
3.3 New Zealand Pharmacogenetic Testing Market - Industry Life Cycle |
3.4 New Zealand Pharmacogenetic Testing Market - Porter's Five Forces |
3.5 New Zealand Pharmacogenetic Testing Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 New Zealand Pharmacogenetic Testing Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.7 New Zealand Pharmacogenetic Testing Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.8 New Zealand Pharmacogenetic Testing Market Revenues & Volume Share, By Sample, 2021 & 2031F |
3.9 New Zealand Pharmacogenetic Testing Market Revenues & Volume Share, By Therapeutic Area, 2021 & 2031F |
3.10 New Zealand Pharmacogenetic Testing Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.11 New Zealand Pharmacogenetic Testing Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 New Zealand Pharmacogenetic Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness among healthcare professionals about the benefits of pharmacogenetic testing |
4.2.2 Growing demand for personalized medicine and precision healthcare solutions |
4.2.3 Government initiatives supporting the adoption of pharmacogenetic testing in healthcare practice |
4.3 Market Restraints |
4.3.1 High initial costs associated with setting up pharmacogenetic testing facilities |
4.3.2 Limited reimbursement policies for pharmacogenetic testing services |
4.3.3 Concerns regarding data privacy and ethical considerations |
5 New Zealand Pharmacogenetic Testing Market Trends |
6 New Zealand Pharmacogenetic Testing Market, By Types |
6.1 New Zealand Pharmacogenetic Testing Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Whole Genome Sequencing, 2021- 2031F |
6.1.4 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Whole Exome Sequencing, 2021- 2031F |
6.1.5 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Array-Based Tests, 2021- 2031F |
6.1.6 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Single Gene Tests, 2021- 2031F |
6.2 New Zealand Pharmacogenetic Testing Market, By Gene Type |
6.2.1 Overview and Analysis |
6.2.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By CYP2C19, 2021- 2031F |
6.2.3 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By CYP2D6, 2021- 2031F |
6.2.4 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By CYP2C9 and VKORC1, 2021- 2031F |
6.2.5 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By CYP1A2, 2021- 2031F |
6.2.6 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By HLA-B*1502, 2021- 2031F |
6.2.7 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By HLA-B*5701, 2021- 2031F |
6.3 New Zealand Pharmacogenetic Testing Market, By Drug Type |
6.3.1 Overview and Analysis |
6.3.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Prescription Drugs, 2021- 2031F |
6.3.3 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Nutraceuticals, 2021- 2031F |
6.3.4 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Recreational Drugs, 2021- 2031F |
6.3.5 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Herbal Supplements, 2021- 2031F |
6.3.6 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Vitamins, 2021- 2031F |
6.3.7 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Over-the-Counter Medications, 2021- 2031F |
6.4 New Zealand Pharmacogenetic Testing Market, By Sample |
6.4.1 Overview and Analysis |
6.4.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Blood, 2021- 2031F |
6.4.3 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Saliva, 2021- 2031F |
6.5 New Zealand Pharmacogenetic Testing Market, By Therapeutic Area |
6.5.1 Overview and Analysis |
6.5.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Cardiology, 2021- 2031F |
6.5.3 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Gastroenterology, 2021- 2031F |
6.5.4 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Anesthesiology, 2021- 2031F |
6.5.5 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Genomics, 2021- 2031F |
6.5.6 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Endocrinology, 2021- 2031F |
6.5.7 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Immunology & Hypersensitivity, 2021- 2031F |
6.5.8 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Others, 2021- 2031F |
6.5.9 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Others, 2021- 2031F |
6.6 New Zealand Pharmacogenetic Testing Market, By Application |
6.6.1 Overview and Analysis |
6.6.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Clinical Practice, 2021- 2031F |
6.6.3 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Drug Development, 2021- 2031F |
6.6.4 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Drug Regulation, 2021- 2031F |
6.7 New Zealand Pharmacogenetic Testing Market, By End User |
6.7.1 Overview and Analysis |
6.7.2 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Healthcare Providers, 2021- 2031F |
6.7.3 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Pharmaceutical & Biotechnology Companies, 2021- 2031F |
6.7.4 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Others, 2021- 2031F |
6.7.5 New Zealand Pharmacogenetic Testing Market Revenues & Volume, By Others, 2021- 2031F |
7 New Zealand Pharmacogenetic Testing Market Import-Export Trade Statistics |
7.1 New Zealand Pharmacogenetic Testing Market Export to Major Countries |
7.2 New Zealand Pharmacogenetic Testing Market Imports from Major Countries |
8 New Zealand Pharmacogenetic Testing Market Key Performance Indicators |
8.1 Number of healthcare professionals trained in pharmacogenetic testing |
8.2 Adoption rate of pharmacogenetic testing in clinical practice |
8.3 Number of government-funded projects or initiatives related to pharmacogenetic testing |
9 New Zealand Pharmacogenetic Testing Market - Opportunity Assessment |
9.1 New Zealand Pharmacogenetic Testing Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 New Zealand Pharmacogenetic Testing Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
9.3 New Zealand Pharmacogenetic Testing Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.4 New Zealand Pharmacogenetic Testing Market Opportunity Assessment, By Sample, 2021 & 2031F |
9.5 New Zealand Pharmacogenetic Testing Market Opportunity Assessment, By Therapeutic Area, 2021 & 2031F |
9.6 New Zealand Pharmacogenetic Testing Market Opportunity Assessment, By Application, 2021 & 2031F |
9.7 New Zealand Pharmacogenetic Testing Market Opportunity Assessment, By End User, 2021 & 2031F |
10 New Zealand Pharmacogenetic Testing Market - Competitive Landscape |
10.1 New Zealand Pharmacogenetic Testing Market Revenue Share, By Companies, 2024 |
10.2 New Zealand Pharmacogenetic Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here